Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal

Biohaven's epilepsy drug development has hit an FDA clinical hold shortly after securing a $350 million deal, delaying potential market entry and affecting business plans.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.